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Abstract
Objective—To evaluate the validity of self-reported lipid medication use in an epidemiological 
study.
Methods—We studied medication self-reports compared with inventoried lipid medication 
containers at the fifth visit of the Atherosclerosis Risk in Communities Study (ARIC) in 2011–
2013 (n=6,370). To assess the validity of self-reports, we computed sensitivity, specificity, 
positive and negative predictive values. We used multiple logistic regression to determine whether 
validity varied by participant characteristics. Comparisons were made with visit 4 (n=11,531), to 
determine if there was a change in validity as the pattern and types of lipid medication used 
changed over time.
Results—The prevalence of lipid medication use, according to medication containers was higher 
at visit 5 (56%) than visit 4 (14.3%). Statins were increasingly used. The percentage of 
participants reporting use/ non-use accurately was 91.8% at visit 5, lower than visit 4 (97.3%). The 
unadjusted kappa coefficient of agreement was 0.83 (95% CI – 0.82 to 0.85) at visit 5 and 0.89 
(95% CI – 0.88 to 0.90) at visit 4. Agreement was higher, compared with their counterparts, for 
women, younger and more educated participants, and those using fewer total medications.
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Conclusion—In this population sample, self-reported lipid medication use was highly accurate 
and therefore likely would be for similar epidemiological studies or clinical settings collecting this 
information.
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1. Introduction
Epidemiological research studies or clinical settings often require people to self-report their 
medications. Understanding the validity and quality of self-reported medication data 
therefore is vital.
Some previous studies have documented the accuracy of recall of medication histories in 
clinical care settings. Hulka et al [1] reported that only about 27% of study participants with 
congestive heart failure were able to accurately recollect their therapeutic regimes. Another 
study showed high accuracy of recall of duration of use and names of most recent oral 
contraceptive drug regimens [2]. Parental recall of children’s inhaled corticosteroid use was 
found to be highly accurate [3]. Yet, only 68% of the drug use information collected at home 
from patients of a specialized geriatric outpatient care clinic agreed with the clinic data [4]. 
Of various medication types assessed, self-report of beta-blockers and centrally acting 
hypertensive medication use was more likely to disagree with clinic data than others [4]. 
Also, the presence of co-morbidities and use of multiple drug regimens in this older 
population decreased recall accuracy [4]. The accuracy of patient recall is reported to vary 
by clinical care setting, type of medication under consideration, patient condition and 
disease severity, doctor-patient relationship, demographic characteristics, past or current 
medication recall, and clinical factors [1–11].
Few studies have reported the accuracy of cardiovascular medication recall data. The 
Cardiovascular Health Study showed modest levels of agreement between directed recall of 
use of beta-blockers and beta-agonists compared with a medication inventory [12]. In 
addition to assessing reliability, authors also used physiologic markers of drug effect to 
assess validity and found that the medication inventory was superior to the directed recall 
[12]. Consistent with findings from similar studies on other medication types, in the 
Rotterdam Elderly Study [13], agreement between self-report and pharmacy records varied 
from poor to perfect by class of cardiovascular medication used. Commonly prescribed 
antihypertensive agents were self-reported with high accuracy (kappa = 0.90 to 0.96), while 
kappas of agreement for organoheparinoids and nitroglycerin were low (kappa = 0.26 – 
0.53).
Only a few studies have assessed the accuracy of recall of lipid medication use. Researchers 
found a generally high sensitivity of recall of statin medication used in the past 6 months 
among older female controls (Sensitivity = 0.93, Specificity = 0.98) and cases with breast 
cancer (Sensitivity = 0.85, Specificity = 0.98) [14]. This recall accuracy decreased slightly 
among both cases and controls for 2-year and 8-year recalls [14]. The study also noted that 
although accuracy of self-report was generally high for statins, it was lower than for 
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antihypertensive drugs. Cardiovascular epidemiological studies often ask about the use of 
lipid lowering medications, but the accuracy of self-reported anti-hyperlipidemic medication 
is not well documented.
Our study therefore measured the validity of patient self-report of lipid medication use in a 
population-based cohort study, the Atherosclerosis Risk in Communities (ARIC) Study. We 
also examined whether there was a change in validity as patterns of lipid medication use 
evolved between 1996–98 and 2011–13.
2. Methods
The ARIC study is a prospective cohort study comprised of 15,792 men and women in 4 
communities: Forsyth County, NC, Jackson, MS, suburban Minneapolis, MN and 
Washington County, MD. At baseline, in 1987–1989, the participants were between 45 and 
64 years and were selected either by list or area probability sampling [15]. ARIC performed 
four examinations of the cohort between 1987 and 1998, and conducted annual telephone 
interviews. The present study is mainly based on the fifth visit in 2011–2013, but with some 
data from the fourth visit in 1996–1998. Among 10,036 ARIC original cohort members 
deemed alive, 6,538 participated in visit 5 resulting in an overall response rate of 65% [16]. 
The visit 4 response rate was 80%. The institutional review board at each site approved the 
ARIC study protocol, and each participant supplied informed consent.
Study participants were instructed to bring to visit 5, the containers of all medications used 
in the past four weeks. If a participant forgot to bring any medication containers, he/she was 
telephoned later for this information. The medication containers were used to create a 
detailed medication inventory which is being used in this analysis as the gold standard to 
evaluate the validity of self-reports. The inventory was created by scanning barcodes on 
medication containers, with the scanning system directly linked to a medication database. 
When a barcode was missing, a medication was not identified by the database, or unmarked 
containers/loose pills were to be inventoried, the interviewer manually transcribed the 
medication using a predetermined protocol. Medication inventories have been found to be a 
reasonably accurate method for ascertaining cardiovascular medication use in the elderly, 
even though this method may generate higher estimates of prevalence of medication use as 
compared to serum levels [11, 16]. Self-report of lipid medication use was ascertained from 
the question, "Were any of the medications you took during the last four weeks for high 
blood cholesterol?” which was recorded as “Yes”, “No” or “Unknown”. We excluded 
participants whose medication container record was missing (n = 26); self-report of 
medication use was missing (n = 39) or ‘Unknown’ (n = 89); or both medication records and 
self-reported were missing (n = 14). Our final analytic sample for Visit 5 included 6,370 
participants (97% of all visit 5 participants, Figure 1).
Comparisons were made with medications reported and recorded at ARIC visit 4 to 
determine whether there was a change in validity as the pattern and types of lipid medication 
used changed over time. At visit 4 staff entered medication names by hand and they were 
linked to a medication database. The fourth visit analytic sample, after excluding 
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observations with missing or unknown medication information (n=125), included 11,531 
participants (99% of all visit 4 participants).
2.1. Statistical Analysis
We computed the sensitivity, specificity, positive predictive value and negative predictive 
value to determine the validity of the self-reported use of lipid medication as compared to 
the gold standard, the medication container records. Sensitivity represents the proportion of 
those who brought in a lipid medication container who reported use. Specificity represents 
the proportion who had no lipid medication container who reported no use. The positive 
predicative value represents the proportion who reported use who actually had a lipid 
medication container. The negative predictive value represents the proportion who reported 
not using a lipid medication who had no lipid medication container. We also calculated 
unadjusted, and prevalence- and bias-adjusted, kappa coefficients [17] (measures of 
agreement) and their respective 95% confidence intervals. To study factors related to 
accurate self-reporting, we created a dichotomous variable of agreement (Yes/No) between 
self-report and medication containers. Using multiple logistic regression, we examined 
whether accuracy varied by the number of medications used, age, sex, race, education, 
combined variable of prevalent cardiovascular disease (CVD) and CVD risk, and study 
center. The combined variable of prevalent CVD and CVD risk was created as follows. 
Study participants were first categorized based on the presence of prevalent CVD by ARIC 
criteria. Those without prevalent CVD were further categorized by CVD risk (>= 7.5% or < 
7.5%) based on American College of Cardiology and American Heart Associations’ 
combined guidelines on the assessment of CVD risk [18]. The three resultant categories of 
this combined variable were: 1) Prevalent CVD, 2) No prevalent CVD, but CVD risk >= 
7.5% and 3) No prevalent CVD, and CVD risk < 7.5%. All analyses were performed using 
SAS (version 9.3).
3. Results
The mean (range) of participant ages was 76.7 (66 to 90) years at visit 5 and 62.8 (52 to 75) 
at visit 4, and the percentages of women were 56% and 59%, respectively. As shown in 
Table 1, according to the medication containers, 61.6% of visit 5 participants currently used 
some lipid medication, as compared with only 14.6% at visit 4. Statins were the most 
commonly used type of lipid medication at both visits (85.0% and 75.7% at visits 4 and 5 
respectively), followed by fibrates, ezetimibe, niacin, bile sequestrants and other types 
during visit 5. Other lipid medications included omega-3 fatty acids, etc. The relative use of 
statins increased and that of fibrates, niacin and bile sequestrants decreased from visit 4 to 
visit 5.
At visit 5, 91.8% of the participants accurately self-reported the use or non-use of lipid 
medication (Table 2). On the other hand, 97.3% of participants had correctly self-reported 
lipid medication use at visit 4, fifteen years earlier. At visit 5, the sensitivity and specificity 
of self-reported lipid medication use when compared with the medication containers was 
0.91 and 0.93 respectively (Table 3). These measures of agreement were slightly higher at 
visit 4. The kappa coefficient of agreement between self-report and medication containers at 
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visit 5 was 0.83 (95% CI – 0.82 to 0.85) and that for visit 4 was 0.89 (95% CI – 0.88 to 
0.90), which did not change after prevalence and bias adjustment. Restriction of the visit 4 
sample to only those who also came to visit 5 yielded similar estimates of percent 
agreements and kappa coefficients.
The mean number of medications of any type recorded in the medication record was 8.9 in 
visit 5, compared with 5.2 in visit 4. The accuracy of recall of lipid meds was inversely 
associated with the number of medications taken. For visit 5, lipid medication kappas were 
0.85, 0.84, 0.81, and 0.76 for participants who took 0–6, 7–8, 9–12, or 13+ total medications 
respectively. For visit 4, the kappa coefficients for the same total medication categories were 
0.90, 0.89, 0.85, and 0.82.
As shown in Table 4, at visit 5, men were 39% less likely to accurately report lipid 
medication use as compared to women. The validity of self-report was lower among older 
adults than their younger counterparts: the third and fourth quartiles of age were both 26% 
less likely to accurately self-report that the first (youngest) quartile of age. Individuals with 
basic education were significantly less likely to accurately report lipid medication use 
compared to those with advanced education. The total number of medications used was 
inversely associated with accuracy of self-report. Individuals using 13 or more total 
medications were 41% less likely accurately report compared to those using 0–6 
medications. Race and study center were not independently associated with accuracy of self-
reported lipid medication use. A combined variable reflecting the participant’s predicted 
cardiovascular risk or the prevalence of cardiovascular disease was not statistically 
significantly associated with the accuracy of recall of lipid medication use (data not shown).
4. Discussion
Clinical trials have documented that the use of lipid-lowering medication, particularly 
statins, reduces the risk of incident and recurrent cardiovascular disease [19]. Therefore, it is 
important for clinical and research purposes to document whether patients accurately report 
lipid medication use. To the best of our knowledge, this is the first general population study 
in the US to validate that participant recall of lipid medication use has a high level of 
accuracy. We also found that as the cohort aged and the prevalence of antihyperlipidemic 
medications, particularly statins, increased over the 15 years between ARIC visit 4 and visit 
5, the validity of self-report went down only slightly. Rising use of statins is consistent with 
the fact that evidence-based guidelines have increasingly recommended the use of lipid 
medications for cardiovascular disease prevention over time [19].
Existing literature suggests that medication self-reports vary across populations, settings, 
and medication types, and likely are affected by doctor-patient communications, patient 
compliance, and individuals’ health conditions. We further showed that validity of self-
reported lipid medication use varied by several demographic characteristics and validity was 
less for patients taking more medications. Thus, the decline in accurate reporting of lipid 
medication use from visit 4 (97.3%) to visit 5 (91.8%) may be due to greater medication use 
or poorer cognitive function at the latter visit. Yet, the validity of self-report of lipid 
medication, overall, seems relatively high for epidemiological research. Moreover, 
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controlling for commonly available variables like gender and age in analyses that use self-
reported measures of lipid medication use could help adjust for inaccurate reporting. Hence, 
findings of our study show patterns consistent with those of previously cited studies 
measuring the accuracy of recall of other cardiovascular medications among older adults 
[11–14]. Results of our analysis provide useful information for various epidemiological 
studies that depend on self-reported data to determine lipid medication use. In addition, our 
study is relevant to national studies like NHANES, which record lipid medication use 
through a similar questionnaire as the one used in ARIC [20].
Results from this study should be interpreted keeping its limitations in mind. While 
considerable effort was taken to ensure that participants produced all medication containers, 
some lipid medications could have been missed or miscoded. Although ARIC is community-
based, it is not representative of the entire U.S., and the response rate to ARIC visit 5 was 
only 65% of those still alive. Those who took part tended to have fewer risk factors and 
health conditions than those who did not [21], and validity may be different for the non-
responders. In addition, by visit 5, ARIC participants had considerable experience in a 
research study, which may have increased their accuracy of self-reported medications.
5. Conclusion
In conclusion, our study established that self-reported lipid medication use is highly accurate 
among ARIC participants and therefore likely would be for similar epidemiological studies 
collecting this information.
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• In a US population study, we assessed validity of self-reported lipid medication 
use.
• 92% of participants reported use/non-use accurately, compared with pill bottles.
• Agreement was higher for women, younger, and more educated participants.
• Agreement was also higher in those using fewer total medications.
• Self-reported lipid medication use seems quite accurate.
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Participant inclusion for analysis;: ARIC Visit 5;, 2011–2013 and ARIC Visit 4, 1996–1998.
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Table 1
Distribution of lipid medications used by ARIC participants according to medication containers, ARIC visit 5 
(2011–2013, n = 6,370) and visit 4 (1996–1998, n = 11,835).
Medication Type Visit 5 - N (%) Visit 4 - N (%)
Total (Any lipid lowering medication) 3921 (61.6a) 1730 (14.6a)
Statin 3331 (85.0) 1309 (75.7)
Fibrate 233 (5.9) 201 (11.6)
Niacin 127 (3.2) 148 (8.6)
Bile Sequestrant 53 (1.4) 72 (4.2)
Ezetimibe 201 (5.1) -
Others 33 (0.8) -
Abbreviation: ARIC, Atherosclerosis Risk in Communities.
a
% of total analytic sample for respective visits.
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Table 2
Frequency of self-report compared to actual use of lipid medication per medication containers, ARIC Visit 5 
(2011–2013) and Visit 4 (1996–1998).




Yes 3235 (50.8%) 327 (5.1%)
No 197 (3.1%) 2611 (41.0%)
ARIC Visit 4
Yes 1515 (13.1%) 140 (1.2%)
No 170 (1.5%) 9706 (84.2%)
Abbreviation: ARIC, Atherosclerosis Risk in Communities.
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Table 3
Validity of self-report of lipid medication use, ARIC visit 5 (2011–2013) and visit 4 (1996–1998).
Measure of validity Visit 5 Visit 4
Sensitivity 0.91 0.92
Specificity 0.93 0.98
Positive Predictive Value 0.94 0.90
Negative Predictive Value 0.89 0.99
Kappa Coefficient (95% Confidence Interval) 0.83 (0.82 – 0.85) 0.89 (0.88 – 0.90)
Abbreviation: ARIC, Atherosclerosis Risk in Communities.
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Table 4
Adjusted odds ratios for agreement between self-report and medication containers by demographic 






Women (n = 3745) 1 (reference) -
Men (n = 2625) 0.61c 0.50–0.73
Age
66 to 71 (n = 1654) 1 (reference) -
72 to 75 (n = 1749) 0.95 0.73–1.25
76 to 79 (n = 1380) 0.74c 0.57–0.97
> 79 (n = 1587) 0.74c 0.57–0.95
Raceb
White (n = 4861) 1 (reference) -
African-American (n = 1491) 0.64 0.36–1.51
Education level
Advanced (n = 2771) 1 (reference) -
Intermediate (n = 2649) 0.85 0.69–1.04
Basic (n = 939) 0.70c 0.54–0.92
Number of medications used
0 to 6 (n = 2056) 1 (reference) -
7 to 8 (n = 1169) 0.82 0.62–1.07
9 to 12 (n = 1859) 0.72c 0.56–0.91
13 or more (n = 1286) 0.59c 0.46–0.77
Center
Minneapolis, MN (n = 1882) 1 (reference) -
Washington County, MD (n = 1716) 0.98 0.75–1.27
Jackson, MS (n = 1367) 0.89 0.47–1.67
Forsyth County, NC (n = 1405) 0.86 0.65–1.12
Abbreviation: ARIC, Atherosclerosis Risk in Communities.
a
Adjusted for all variables shown.
b
Asian and American Indian participants were excluded due to very small sample sizes.
c
Odds ratio significantly different from 1 at p<0.05.
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